Creative Planning Buys 31,617 Shares of Stoke Therapeutics, Inc. $STOK

Creative Planning raised its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 251.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 44,215 shares of the company’s stock after buying an additional 31,617 shares during the quarter. Creative Planning’s holdings in Stoke Therapeutics were worth $502,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of STOK. AlphaQuest LLC bought a new position in shares of Stoke Therapeutics in the first quarter valued at approximately $72,000. US Bancorp DE lifted its stake in Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after purchasing an additional 11,108 shares in the last quarter. Fox Run Management L.L.C. bought a new position in Stoke Therapeutics in the 1st quarter valued at $92,000. Russell Investments Group Ltd. purchased a new position in shares of Stoke Therapeutics during the 1st quarter valued at $107,000. Finally, Police & Firemen s Retirement System of New Jersey grew its position in shares of Stoke Therapeutics by 33.2% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock valued at $108,000 after purchasing an additional 2,384 shares in the last quarter.

Insider Activity

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 8,785 shares of the business’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $31.29, for a total value of $274,882.65. Following the completion of the sale, the general counsel directly owned 15,809 shares of the company’s stock, valued at $494,663.61. The trade was a 35.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Barry Ticho sold 3,662 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $31.34, for a total transaction of $114,767.08. Following the sale, the insider owned 19,798 shares of the company’s stock, valued at approximately $620,469.32. The trade was a 15.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 164,758 shares of company stock valued at $4,575,161. Corporate insiders own 9.50% of the company’s stock.

Stoke Therapeutics Trading Down 0.6%

Shares of Stoke Therapeutics stock opened at $30.87 on Friday. The firm has a market capitalization of $1.76 billion, a PE ratio of 46.07 and a beta of 1.14. The business’s 50-day moving average price is $29.03 and its 200-day moving average price is $19.83. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.The firm had revenue of $10.63 million during the quarter, compared to the consensus estimate of $6.06 million. As a group, analysts predict that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Canaccord Genuity Group increased their price objective on Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Chardan Capital raised Stoke Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. BTIG Research reiterated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 5th. JPMorgan Chase & Co. upped their price objective on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a research report on Monday, November 3rd. Finally, Wedbush raised their target price on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a research note on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $31.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.